Safer alternative to controversial blood thinner heparin createdAugust 18th, 2008 - 12:55 pm ICT by ANI
Washington, August 18 (ANI): A team of researcher from Rensselaer Polytechnic Institute in New York has announced the creation of a safer alternative to the commonly used and controversial blood thinner heparin.
While making a presentation on their work at the national conference of the American Chemical Society on Sunday, the researchers insisted that their creation was the largest dose of heparin ever created in the lab.
The main source of heparin is the intestines of foreign livestock, and the risk of contamination from such sources is high.
In the spring of 2008, more than 80 people around the world died, and hundreds became ill after being administered what was believed to be contaminated batches of heparin.
Robert Linhardt, a member of the international team that was formed to search for a safer alternative to the common drug, has revealed that they identified the suspected contaminant in the Chinese heparin, a structurally similar carbohydrate called oversulfated chondroitin sulfate.
“When we found the contamination, it was another sign that the way we currently manufacture heparin is simply unsafe. Unlike the current heparin that is harvested from possibly disease carrying animals in often very poor conditions, our fully synthetic heparin will be created in a pharmaceutical manufacturing environment from fermentation to packaging. This will give drug manufacturers extreme control over the safety and purity of the product,” he said.
Working in collaboration with Jian Liu of the University of North Carolina, Linhardt discovered the synthetic “recipe” for heparin in 2006.
He had since been working to piece together the various molecules and grow in the lab a complex carbohydrate, which is naturally created in the body.
According to Linhardt, the carbohydrate backbone for the new heparin comes from the bacteria E. coli, and the use of the common and easily grown bacteria makes this version of heparin much easier and faster to produce.
He and his colleagues used a process called chemoenzymatic synthesis that used specialized synthetic chemicals and natural enzymes expressed in E. coli to replicate the normal biosynthesis of natural heparin within the cell.
The dose that the researchers were able to produce with the new approach was a million times higher than any other alternative created to date.
Linhardt says that he will continue to work with his partners to take the milligram dose that they have developed and expand it to kilograms.
“Ultimately, drug companies are going to need to produce tons of this drug to keep up with global demand. Such levels of productions are further down the road. We think that in five years, it is very possible that this drug could reach human clinical trials,” he said. (ANI)
- Source of lethal contamination in heparin drug uncovered - Apr 26, 2008
- New method can detect contaminants in life-saving drug - Nov 18, 2008
- Food poisoning bacteria may be key to future of renewable energy - Sep 04, 2010
- Molecule from shark cartilage fights joint pain - Sep 18, 2011
- Marine life inspires new chemical-free, anti-bacteria plastic 'skins' - Dec 29, 2010
- Cattle vaccine can halve E. coli levels - Aug 07, 2012
- UAE teaches farmers about E.coli - Jun 28, 2011
- Bugs filch copper to spread urinary infections - Jul 09, 2012
- Bacterial defense mechanism code cracked - Apr 26, 2010
- Nitric oxide can ward off deadly infections - Jul 24, 2011
- Discovery paves way for safer drinking water, cheaper medicine - May 27, 2010
- New antibiotic to treat adulterated food - Aug 07, 2011
- 'Dip Chip' warns of toxicity in real time - May 15, 2012
- 15 tonnes of methamphetamine seized in Mexico - Feb 10, 2012
- Programming bacteria to act like mini computers - Dec 09, 2010
Tags: american chemical society, complex carbohydrate, disease carrying animals, drug manufacturers, extreme control, heparin, jian liu, pharmaceutical manufacturing, rensselaer polytechnic institute, university of north carolina